References

  1. 1.Seay NW, Lehrich RW, Greenberg A. Diagnosis and management of disorders of body tonicity-hyponatremia and hypernatremia: core curriculum 2020. Am J Kidney Dis. 2020;75(2):272-286.
  2. 2.DeVita MV, Gardenswartz MH, Konecky A, et al. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol. 1990;34(4):163-166.
  3. 3.Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003;337(1):169-172.
  4. 4.Spasovski G, Vanholder R, Allolio B, et al.; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1-G47.
  5. 5.Wald R, Jaber BL, Price LL, et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294-302.
  6. 6.See XY, Chang YC, Peng CY, et al. Rate of sodium correction and osmotic demyelination syndrome in severe hyponatremia: a meta-analysis. J Crit Care Med (Targu Mures). 2024;10(3):209-212.
  7. 7.Shekar RG, Rodha MS, Sharma A, et al. Short-term outcomes of patients with hyponatremia presenting to the emergency department: an observational study. Cureus. 2024;16(7):e63679.
  8. 8.Feld LG, Neuspiel DR, Foster BA, et al.; Subcommittee on Fluid and Electrolyte Therapy. Clinical practice guideline: maintenance intravenous fluids in children. Pediatrics. 2018;142(6):e20183083.
  9. 9.Renneboog B, Sattar L, Decaux G. Attention and postural balance are much more affected in older than in younger adults with mild or moderate chronic hyponatremia. Eur J Intern Med. 2017;41:e25-e26.
  10. 10.Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):71.e1-71.e8.
  11. 11.Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28(5):1340-1349.
  12. 12.Alindogan A, Joseph R. Disorders of sodium. Emerg Med Clin North Am. 2023;41(4):697-709.
  13. 13.Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10):S1-S42.
  14. 14.Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106(4):399-403.
  15. 15.O’Connor RE. Exercise-induced hyponatremia: causes, risks, prevention, and management. Cleve Clin J Med. 2006;73:S13-S18.
  16. 16.Nigro N, Winzeler B, Suter-Widmer I, et al. Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: ‘The Co-MED Study’. Clin Endocrinol (Oxf). 2017;86(3):456-462.
  17. 17.Ayus JC, Moritz ML, Fuentes NA, et al. Correction rates and clinical outcomes in hospitalized adults with severe hyponatremia: a systematic review and meta-analysis. JAMA Intern Med. 2025;185(1):38-51.
  18. 18.Schrier RW, Gross P, Gheorghiade M, et al.; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099-2112.
  19. 19.Lindner G, Funk GC, Schwarz C, et al. Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis. 2007;50(6):952-957.
  20. 20.Yun G, Baek SH, Kim S. Evaluation and management of hypernatremia in adults: clinical perspectives. Korean J Intern Med (Korean Assoc Intern Med). 2023;38(3):290-302.
  21. 21.Arampatzis S, Frauchiger B, Fiedler GM, et al. Characteristics, symptoms, and outcome of severe dysnatremias present on hospital admission. Am J Med. 2012;125(11):1125.e1-1125.e7.
  22. 22.Odier C, Nguyen DK, Panisset M. Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis. J Neurol. 2010;257(7):1176-1180.
  23. 23.Ismail FY, Szóllics A, Szólics M, et al. Clinical semiology and neuroradiologic correlates of acute hypernatremic osmotic challenge in adults: a literature review. AJNR Am J Neuroradiol. 2013;34(12):2225-2232.
  24. 24.Arzhan S, Roumelioti M, Litvinovich I, et al. Outcomes of hospital-acquired hypernatremia. Clin J Am Soc Nephrol. 2023;18(11):1396-1407.
  25. 25.Leung AA, McAlister FA, Finlayson SRG, et al. Preoperative hypernatremia predicts increased perioperative morbidity and mortality. Am J Med. 2013;126(10):877-886.
  26. 26.Timper K, Fenske W, Kühn F, et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. J Clin Endocrinol Metab. 2015;100(6):2268-2274.
  27. 27.Didsbury M, See EJ, Cheng DR, et al. Correcting hypernatremia in children. Clin J Am Soc Nephrol. 2023;18(3):306-314.
  28. 28.Chauhan K, Pattharanitima P, Patel N, et al. Rate of correction of hypernatremia and health outcomes in critically ill patients. Clin J Am Soc Nephrol. 2019;14(5):656-663.
  29. 29.Bolat F, Oflaz MB, Güven AS, et al. What is the safe approach for neonatal hypernatremic dehydration? A retrospective study from a neonatal intensive care unit. Pediatr Emerg Care. 2013;29(7):808-813.
  30. 30.Alshayeb HM, Showkat A, 0 F, et al. Severe hypernatremia correction rate and mortality in hospitalized patients. Am J Med Sci. 2011;341(5):356-360.
  1. 1.Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical update. Endocr Connect. 2018;7(4):R135-R146.
  2. 2.Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ. 2016;40(4):480-490.
  3. 3.Mahmud HA, Palmer BF. Management of hyperkalemia in reninangiotensin-aldosterone system inhibitor: strategies to maintain chronic kidney disease patients with type II diabetes on therapy. Cardiorenal Med. 2024;14(1):191-201.
  4. 4.Squires RD, Huth EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest. 1959;38(7):1134-1148.
  5. 5.Alderman MH, Piller LB, Ford CE, et al.; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59(5):926-933.
  6. 6.Clase CM, Carrero JJ, Ellison DH, et al.; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61.
  7. 7.Kim MJ, Valerio C, Knobloch GK. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician. 2023;107(1):59-70.
  8. 8.Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992;267(8):1083-1089.
  9. 9.Rodenburg EM, Visser LE, Hoorn EJ, et al. Thiazides and the risk of hypokalemia in the general population. J Hypertens. 2014;32(10):2092-2097.
  10. 10.Hooft van Huysduynen EJ, Hulshof PJM, van Lee L, et al. Evaluation of using spot urine to replace 24 h urine sodium and potassium excretions. Public Health Nutr. 2014;17(11):2505-2511.
  11. 11.Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744-762.
  12. 12.Korgaonkar S, Tilea A, Gillespie BW, et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol. 2010;5(5):762-769.
  13. 13.Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(22):2836-2850.
  14. 14.Gennari FJ. Hypokalemia. N Engl J Med. 1998;339(7):451-458.
  15. 15.Asmar A, Mohandas R, Wingo CS. A physiologic-based approach to the treatment of a patient with hypokalemia. Am J Kidney Dis. 2012;60(3):492-497.
  16. 16.Kassirer JP, Berkman PM, Lawrenz DR, et al. The critical role of chloride in the correction of hypokalemic alkalosis in man. Am J Med. 1965;38(2):172-189.
  17. 17.Cohn JN, Kowey PR, Whelton PK, et al. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160(16):2429-2436.
  18. 18.Sevamontree C, Jintajirapan S, Phakdeekitcharoen P, et al. The prevalence and risk factors of hyperkalemia in the outpatient setting. Int J Nephrol. 2024;2024:5694131.
  19. 19.Palmer BF, Clegg DJ. Hyperkalemia treatment standard. Nephrol Dial Transplant. 2024;39(7):1097-1104.
  20. 20.Ben Salem C, Badreddine A, Fathallah N, et al. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677-692.
  21. 21.Gilligan S, Raphael KL. Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes. Adv Chronic Kidney Dis. 2017;24(5):315-318.
  22. 22.Surawicz B, Chlebus H, Mazzoleni A. Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K. Am Heart J. 1967;73(5):647-664.
  23. 23.Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3(2):324-330.
  24. 24.Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant. 2002;17(9):1639-1642.
  25. 25.Stevens PE, Ahmed SB, Carrero JJ, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117-S314.
  26. 26.Liamis G, Liberopoulos E, Barkas F, et al. Spurious electrolyte disorders: a diagnostic challenge for clinicians. Am J Nephrol. 2013;38(1):50-57.
  27. 27.Alfonzo A, Harrison A, Baines R, et al. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. AlfonzoAHarrisonABainesRet al. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. UK Kidney Association; 2023.
  28. 28.Singer AJ, Thode HC Jr, Peacock WF. Rapid correction of hyperkalemia is associated with reduced mortality in ED patients. Am J Emerg Med. 2020;38(11):2361-2364.
  29. 29.Sinnathamby ES, Banh KT, Barham WT, et al. Hyperkalemia: pharmacotherapies and clinical considerations. Cureus. 2024;16(1):e52994.
  30. 30.DailyMed. Calcium gluconate injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16307c00-d0d5-4e05-821f-17b0c1a29fc9
  31. 31.Cook ME, Tran LK, DeGrado JR, et al. Evaluation of insulin dosing strategies for hyperkalemia management at an academic medical center. Clin Ther. 2024;46(5):382-388.
  32. 32.Long B, Warix JR, Koyfman A. Controversies in management of hyperkalemia. J Emerg Med. 2018;55(2):192-205.
  33. 33.Arzayus-Patiño L, Hinojosa-Angulo AY, Rodriguez-Angulo KA, et al. Utility of inhaled β2-agonists in reducing serum potassium levels in adult patients with hyperkalemia: a scoping review. PLoS One. 2026;21(2):e0342309.
  34. 34.Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalaemia in adults. Cochrane Database Syst Rev. 2015;10(10):CD010344.
  35. 35.De Nicola L, Ferraro PM, Montagnani A, et al. Recommendations for the management of hyperkalemia in patients receiving reninangiotensin-aldosterone system inhibitors. Intern Emerg Med. 2024;19(2):295-306.
  36. 36.Gaudry S, Palevsky PM, Dreyfuss D. Extracorporeal kidney-replacement therapy for acute kidney injury. N Engl J Med. 2022;386(10):964-975.
  1. 1.Hamm LL, Nakhoul N, Hering-Smith KS. Acid-base homeostasis. Clin J Am Soc Nephrol. 2015;10(12):2232-2242.
  2. 2.Berend K, de Vries APJ, Gans ROB. Physiological approach to assessment of acid-base disturbances. N Engl J Med. 2014;371(15):1434-1445.
  3. 3.Palmer BF, Clegg DJ. Respiratory acidosis and respiratory alkalosis: core curriculum 2023. Am J Kidney Dis. 2023;82(3):347-359.
  4. 4.Weiner ID, Verlander JW. Ammonia transporters and their role in acid-base balance. Physiol Rev. 2017;97(2):465-494.
  5. 5.Chia CYP, Poulose V, How CH. Approach to acid-base disorders in primary care. Singapore Med J. 2024;65(2):106-110.
  6. 6.Funk GC, Zauner C, Bauer E, et al. Compensatory hypochloraemic alkalosis in diabetic ketoacidosis. Diabetologia. 2003;46(6):871-873.
  7. 7.Kitterer D, Schwab M, Alscher MD, et al. Drug-induced acid-base disorders. Pediatr Nephrol. 2015;30(9):1407-1423.
  8. 8.Scheiner B, Lindner G, Reiberger T, et al. Acid-base disorders in liver disease. J Hepatol. 2017;67(5):1062-1073.
  9. 9.Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(2):263-275.
  10. 10.Chong WH, Saha BK, Medarov BI. Comparing central venous blood gas to arterial blood gas and determining its utility in critically ill patients: narrative review. Anesth Analg. 2021;133(2):374-378.
  11. 11.Peixoto AJ, Alpern RJ. Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis. 2013;61(5):822-827.
  12. 12.Achanti A, Szerlip HM. Acid-base disorders in the critically ill patient. Clin J Am Soc Nephrol. 2023;18(1):102-112.
  13. 13.Fenves AZ, Emmett M. Approach to patients with high anion gap metabolic acidosis: core curriculum 2021. Am J Kidney Dis. 2021;78(4):590-600.
  14. 14.Lentz SA, Ackil D. Metabolic acid-base disorders. Emerg Med Clin North Am. 2023;41(4):849-862.
  15. 15.Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010;6(5):274-285.
  16. 16.Vichot AA, Rastegar A. Use of anion gap in the evaluation of a patient with metabolic acidosis. Am J Kidney Dis. 2014;64(4):653-657.
  17. 17.Cao S, Cao S. Diabetic ketoalkalosis: a common yet easily overlooked alkalemic variant of diabetic ketoacidosis associated with mixed acid-base disorders. J Emerg Med. 2023;64(3):282-288.
  18. 18.Do C, Vasquez PC, Soleimani M. Metabolic alkalosis pathogenesis, diagnosis, and treatment: core curriculum 2022. Am J Kidney Dis. 2022;80(4):536-551.
  19. 19.Arena A, Miller E. Respiratory acid-base disorders. Emerg Med Clin North Am. 2023;41(4):863-875.
  20. 20.Foster GT, Vaziri ND, Sassoon CS. Respiratory alkalosis. Respir Care. 2001;46(4):384-391.
  21. 21.Liamis G, Filippatos TD, Liontos A, et al. Serum osmolal gap in clinical practice: usefulness and limitations. Postgrad Med. 2017;129(4):456-459.
  22. 22.Kharsa A, Vashisht R, Rout P, et al. Anion gap and non-anion gap metabolic acidosis. https://www.ncbi.nlm.nih.gov/books/NBK448090/
  23. 23.Sharma S, Hashmi MF, Aggarwal S. Hyperchloremic acidosis (archived). https://www.ncbi.nlm.nih.gov/books/NBK482340/
  24. 24.Latif A, Thirumalareddy J, Sood A, et al. First reported case of hyperchloremic non-anion gap metabolic acidosis in a patient undergoing continuous bladder irrigation for hemorrhagic cystitis. Cureus. 2020;12(12):e12132.
  25. 25.Tinawi M. Pathophysiology, evaluation, and management of metabolic alkalosis. Cureus. 2021;13(1):e12841.
  26. 26.Epstein SK, Singh N. Respiratory acidosis. Respir Care. 2001;46(4):366-383.
  27. 27.Hopkins E, Sanvictores T, Sharma S. Physiology, acid base balance. https://www.ncbi.nlm.nih.gov/books/NBK507807/&lang=en/
  28. 28.Sanghavi SF, Swenson ER. Arterial blood gases and acid-base regulation. Semin Respir Crit Care Med. 2023;44(5):612-626.
  1. 1.Michels TC, Kelly KM. Parathyroid disorders. Am Fam Physician. 2013;88(4):249-257.
  2. 2.Murray SL, Wolf M. Calcium and phosphate disorders: core curriculum 2024. Am J Kidney Dis. 2024;83(2):241-256.
  3. 3.Wang W, Meng C, Ouyang Q, et al. Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy. Cancer Manag Res. 2019;11:8135-8144.
  4. 4.Walker MD, Shane E. Hypercalcemia: a review. JAMA. 2022;328(16):1624-1636.
  5. 5.Desgagnés N, King JA, Kline GA, et al. Use of albumin-adjusted calcium measurements in clinical practice. JAMA Netw Open. 2025;8(1):e2455251.
  6. 6.Byrnes MC, Huynh K, Helmer SD, et al. A comparison of corrected serum calcium levels to ionized calcium levels among critically ill surgical patients. Am J Surg. 2005;189(3):310-314.
  7. 7.Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the Second International Workshop. J Bone Miner Res. 2022;37(12):2568-2585.
  8. 8.Jesus JE, Landry A. Images in clinical medicine. Chvostek’s and Trousseau’s signs. N Engl J Med. 2012;367(11):e15.
  9. 9.Han P, Trinidad BJ, Shi J. Hypocalcemia-induced seizure: demystifying the calcium paradox. ASN Neuro. 2015;7(2):1-9.
  10. 10.Underbjerg L, Sikjaer T, Mosekilde L, et al. Postsurgical hypoparathyroidism – risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29(11):2504-2510.
  11. 11.Floege J, Tsirtsonis K, Iles J, et al. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int. 2018;93(6):1475-1482.
  12. 12.Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36.
  13. 13.Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28(12):2570-2576.
  14. 14.Ritter K, Elfenbein D, Schneider DF, et al. Hypoparathyroidism after total thyroidectomy: incidence and resolution. J Surg Res. 2015;197(2):348-353.
  15. 15.Palermo A, Santonati A, Tabacco G, et al. PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2018;103(1):271-280.
  16. 16.Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010;85(8):752-757.
  17. 17.Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947.
  18. 18.Lindner G, Felber R, Schwarz C, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med. 2013;31(4):657-660.
  19. 19.Thillainadesan S, Twigg SM, Perera N. Prevalence, causes and associated mortality of hypercalcaemia in modern hospital care. Intern Med J. 2022;52(9):1596-1601.
  20. 20.Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab. 2016;101(3):1166-1173.
  21. 21.Pérez-Barrios C, Hernández-Álvarez E, Blanco-Navarro I, et al. Prevalence of hypercalcemia related to hypervitaminosis D in clinical practice. Clin Nutr. 2016;35(6):1354-1358.
  22. 22.Ghada EF, Clines GH, Hu HI, et al. Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):507-528.
  23. 23.Carnaille B, Oudar C, Pattou F, et al. Pancreatitis and primary hyperparathyroidism: forty cases. Aust N Z J Surg. 1998;68(2):117-119.
  24. 24.Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab. 2011;96(8):2377-2385.
  25. 25.Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis. 2005;45(4):626-637.
  26. 26.Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28(5):1029-1040.
  27. 27.Bilezikian JP, Khan AA, Silverberg SJ, et al.; International Workshop on Primary Hyperparathyroidism. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293-2314.
  28. 28.Arshad MF, McAllister J, Merchant A, et al. Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best?. Postgrad Med J. 2021;97(1151):577-582.
  29. 29.Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132(3):359-372.
  30. 30.Pappachan JM, Lahart IM, Viswanath AK, et al. Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database Syst Rev. 2023;3(3):CD013035.
  31. 31.Tassone F, Guarnieri A, Castellano E, et al. Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(8):3069-3073.
  32. 32.Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93(9):3462-3470.
  33. 33.LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149(4):259-263.
  34. 34.Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-567.
  35. 35.Fatemi S, Singer FR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int. 1992;50(2):107-109.
  36. 36.Cicci JD, Buie L, Bates J, et al. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk. 2014;14(6):e207-e211.
  37. 37.Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: Mechanisms, diagnosis, and treatment. Endocr Rev. 2016;37(5):521-547.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.